Clinical trialNCT01650090CompletedPhase 2Interventional

Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma

SponsorEleison Pharmaceuticals LLC.Enrollment28Pulmonary Relapse of Osteosarcoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

To establish whether treatment with Inhaled Lipid Cisplatin (ILC) is effective in delaying/preventing pulmonary relapse in osteosarcoma patients in complete surgical remission following one or two prior pulmonary relapses.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Forrest H Anthony, MD, PhD
Eleison Pharmaceuticals
Study Director
clinicaltrials.gov ↗
Richard Gorlick, MD
Children's Hospital at Montefiore
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

15 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Children'S Hospital Los Angeles
Los Angeles, California, United States
Stanford University Medical Center
Palo Alto, California, United States
H. Lee Moffitt Cancer Center
Tampa, Florida, United States
University of Chicago
Chicago, Illinois, United States
Ochsner Clinic Foundation
New Orleans, Louisiana, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Mayo Clinic
Rochester, Minnesota, United States
Washington University School of Medicine
St Louis, Missouri, United States
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
the Children'S Hospital at Montefiore
The Bronx, New York, United States
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
Ut Southwestern Medical Center
Dallas, Texas, United States
Baylor College of Medicine/texas Children'S Hospital
Houston, Texas, United States
Primary Children'S Medical Center
Salt Lake City, Utah, United States
Seattle Children'S Hospital
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Inhaled Lipid Cisplatin

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Aug 2012
Primary completion: 30 Nov 2018
Completion: 30 Nov 2018
Last update posted: 7 Aug 2019
Registered enrollment: 28
Registry id: NCT01650090

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.